mdm2 is critical for inhibition of p53 during lymphopoiesis and the response to ionizing irradiation

Molecular and Cellular Biology

Volumn 23, Issue 2, 2003, Pages 462-473

  Mendrysa, Susan M ^a,d   McElwee, Matthew K ^a   Michalowski, Jennifer ^a,c   O'Leary, Kathleen A ^a   Young, Karen M ^b   Perry, Mary Ellen ^a,c  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN INHIBITOR; PROTEIN MDM2; PROTEIN P53;

ALLELE; ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; EMBRYO; GENE ACTIVATION; GENE DELETION; GENE FUNCTION; HOMEOSTASIS; IRRADIATION; LYMPHOPOIESIS; MOUSE; NONHUMAN; NORTHERN BLOTTING; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEGRADATION; TRANSCRIPTION INITIATION; WESTERN BLOTTING;

ALLELES; ANIMALS; APOPTOSIS; BLOTTING, NORTHERN; BLOTTING, WESTERN; BODY WEIGHT; CELL DEATH; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, RADIATION; FLOW CYTOMETRY; GENE DELETION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOTYPE; HEMATOPOIETIC STEM CELLS; IN SITU NICK-END LABELING; LYMPHOCYTES; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MODELS, GENETIC; NUCLEAR PROTEINS; PRECIPITIN TESTS; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; RNA, MESSENGER; TIME FACTORS; TISSUE DISTRIBUTION; TRANS-ACTIVATION (GENETICS); TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

ANIMALIA;

EID: 0037220737     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.23.2.462-473.2003     Document Type: Article

References (61)

1. Barak, Y., T. Juven, R. Haffner, and M. Oren. 1993. mdm2 expression is induced by wild-type p53 activity. EMBO J. 12:461-468.
2. Böttger, A., V. Böttger, A. Sparks, W.-L. Liu, S. F. Howard, and D. P. Lane. 1997. Design of a synthetic MDM2-binding mini protein that activates the p53 response in vivo. Curr. Biol. 7:860-869.
3. Bouvard, V., T. Zaitchouk, M. Vacher, A. Duthu, M. Canivet, C. Choisy-Rossi, M. Nieruchalski, and E. May. 2000. Tissue- and cell-specific expression of the p53 target genes bax, fas, mdm2 and waf1/p21 before and following ionizing irradiation in mice. Oncogene 19:649-660.
4. Chen, L., S. Agrawal, W. Zhou, R. Zhang, and J. Chen. 1998. Synergistic activation of p53 by inhibition of mdm2 expression and DNA damage. Proc. Natl. Acad. Sci. USA 95:195-200.
5. Costanzo, V., K. Robertson, M. Bibikova, E. Kim, D. Grieco, M. Gottesman, D. Carroll, and J. Gutier. 2001. Mre11 protein complex prevents doublestrand break accumulation during chromosomal DNA replication. Mol. Cell 8:137-147.
6. Donehower, L. A., M. Harvey, B. L. Slagle, M. J. McArthur, C. A. Montgomery, Jr., J. S. Butel, and A. Bradley. 1992. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356:215-221.
7. Fakharzadeh, S. S., S. P. Trusko, and D. L. George. 1991. Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. EMBO J. 10:1565-1569.
8. Freedman, D. A., and A. J. Levine. 1998. Nuclear export is required for degradation of endogenous p53 by mdm2 and human papillomavirus E6. Mol. Cell. Biol. 18:7288-7293.
9. Gavrieli, Y., Y. Sherman, and S. A. Ben-Sasson. 1992. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J. Cell Biol. 119:493-501.
10. Gottlieb, E., R. Haffner, A. King, G. Asher, P. Gruss, P. Lonai, and M. Oren. 1997. Transgenic mouse model for studying the transcriptional activity of the p53 protein: Age- and tissue-dependent changes in radiation-induced activation during embryogenesis. EMBO J. 16:1381-1390.
11. Grippo, P. J., P. S. Nowlin, R. D. Cassaday, and E. Sandgren. 2002. Cell-specific transgene expression from a widely transcribed promoter with Cre/Lox in mice. Genesis 32:277-286.
12. Guidos, C. J., C. J. Williams, I. Grandal, G. Knowles, M. T. F. Huang, and J. S. Danska. 1996. V(D)J recombination activates a p53-dependent DNA damage checkpoint in scid lymphocyte precursors. Genes Dev. 10:2038-2054.
13. Harvey, M., A. T. Sands, R. S. Weiss, M. E. Hegi, R. W. Wiseman, P. Pantazis, B. C. Giovanella, M. A. Tainsky, A. Bradley, and L. A. Donehower. 1993. In vitro growth characteristics of embryo fibroblasts isolated from p53-deficient mice. Oncogene 8:2457-2467.
14. Haupt, Y., S. Rowan, E. Shaulian, K. Vousden, and M. Oren. 1995. Induction of apoptosis in HeLa cells by transactivation deficient p53. Genes Dev. 9:2170-2183.
15. Haupt, Y., R. Maya, A. Kazaz, and M. Oren. 1997. MDM2 promotes the rapid degradation of p53. Nature 387:296-299.
16. Hinds, P. W., C. A. Finlay, A. B. Frey, and A. J. Levine. 1987. Immunological evidence for the association of p53 with a heat shock protein, hsc70, in p53-plus-ras-transformed cell lines. Mol. Cell. Biol. 7:2863-2869.
17. Hollstein, M., M. Hergenhahn, Q. Yang, H. Bartsch, Z. Q. Wang, and P. Hainaut. 1999. New approaches to understanding p53 gene mutation spectra. Mutat. Res. 431:199-209.
18. Honda, R., H. Tanaka, and H. Yasuda. 1997. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett. 420:25-27.
19. Ikuta, K., N. Uchida, J. Friedman, and I. L. Weissman. 1992. Lymphocyte development from stem cells. Annu. Rev. Immunol. 10:739-783.
20. Jacks, T., L. Remington, B. O. Williams, E. M. Schmitt, S. Halachmi, R. T. Bronson, and R. A. Weinberg. 1994. Tumor spectrum analysis in p53-mutant mice. Curr. Biol. 4:1-7.
21. Jones, S. N., A. E. Roe, L. A. Donehower, and A. Bradley. 1995. Rescue of embryonic lethality in MDM2-deficient mice by absence of p53. Nature 378:206-208.
22. Juven, T., Y. Barak, A. Zauberman, D. L. George, and M. Oren. 1993. Wild-type p53 can mediate sequence-specific transactivation of an internal promoter within the mdm2 gene. Oncogene 8:3411-3416.
23. Kastan, M. B., O. Onyekwere, D. Sidransky, B. Vogelstein, and R. W. Craig. 1991. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 51:6304-6311.
24. Kastan, M. B., Q. Zhan, W. S. El-Deiry, F. Carrier, T. Jacks, W. V. Walsh, B. S. Plunkett, B. Vogelstein, and A. J. Fornace. 1992. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxiatelangiectasia. Cell 71:587-597.
25. Komarova, E. A., M. V. Chernov, R. Franks, K. Wang, G. Armin, C. R. Zelnick, D. M. Chin, S. S. Bacus, G. R. Stark, and A. V. Gudkov. 1997. Transgenic mice with p53-responsive lacZ: p53 activity varies dramatically during normal development and determines radiation and drug sensitivity in vivo. EMBO J. 16:1391-1400.
26. Komarova, E. A., K. Christov, A. I. Faerman, and A. V. Gudkov. 2000. Different impact of p53 and p21 on the radiation response of mouse tissues. Oncogene 19:3791-3798.
27. Kubbutat, M. H. G., S. N. Jones, and K. H. Vousden. 1997. Regulation of p53 stability by MDM2. Nature 387:299-303.
28. Kubbutat, M. H. G., R. L. Ludwig, A. J. Levine, and K. H. Vousden. 1999. Analysis of the degradation function of MDM2. Cell Growth Differ. 10:87-92.
29. Kuhn, R., F. Schwenk, M. Aguet, and K. Rajewsky. 1995. Inducible gene targeting in mice. Science 269:1427-1429.
30. Leach, F. S., T. Tokino, P. Meltzer, M. Burrell, J. D. Oliner, S. Smith, D. E. Hill, D. Sidransky, K. Kinzler, and B. Vogelstein. 1993. p53 mutation and mdm2 amplification in human soft tissue sarcomas. Cancer Res. 53:2231-2234.
31. Leveillard, T., P. Gorry, K. Niederreither, and B. Wasylyk. 1998. mdm2 expression during mouse embryogenesis and the requirement of p53. Mech. Dev. 74:189-193.
32. Lowe, S. W., H. E. Ruley, T. Jacks, and D. E. Housman. 1993. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74:957-967.
33. Lowe, S. W., S. Bodis, A. McClatchey, L. Remington, H. E. Ruley, D. E. Fisher, D. E. Housman, and T. Jacks. 1994. p53 status and the efficacy of cancer therapy in vivo. Science 266:807-810.
34. MacCallum, D. E., T. R. Hupp, C. A. Midgley, D. Stuart, S. J. Campbell, A. Harper, F. S. Walsh, E. G. Wright, A. Balmain, D. P. Lane, and P. A. Hall. 1996. The p53 response to ionizing radiation in adult and developing murine tissues. Oncogene 13:2575-2587.
35. Macleod, K. F., N. Sherry, G. Hannon, D. Beach, T. Tokino, K. Kinzler, B. Vogelstein, and T. Jacks. 1995. p53-dependent and -independent expression of p21 during cell growth, differentiation and DNA damage. Genes Dev. 9:935-944.
36. McDonnell, T. J., R. Montes de Oca Luna, S. Cho, L. Amelse, A. Chavez-Reyes, and G. Lozano. 1999. Loss of one but not two mdm2 null alleles alters the tumor spectrum in p53 null mice. J. Pathol. 188:322-328.
37. Mendrysa, S. M., and M. E. Perry. 2000. The p53 tumor suppressor protein does not regulate expression of its own inhibitor, MDM2, except under conditions of stress. Mol. Cell. Biol. 20:3023-3030.
38. Mendrysa, S. M., M. K. McElwee, and M. E. Perry. 2001. Characterization of the 5' and 3' untranslated regions in murine mdm2 mRNAs. Gene 264: 139-146.
39. Merritt, A. J., C. S. Potten, C. J. Kemp, J. A. Hickman, A. Balmain, D. P. Lane, and P. A. Hall. 1994. The role of p53 in spontaneous and radiation-induced apoptosis in the gastrointestinal tract of normal and p53-deficient mice. Cancer Res. 54:614-617.
40. Midgley, C. A., B. Owens, C. V. Briscoe, D. B. Thomas, D. P. Lane, and P. A. Hall. 1995. Coupling between gamma irradiation, p53 induction and the apoptotic response depends upon cell type in vivo. J. Cell Sci. 108:1843-1848.
41. ARF peptide blocks MDM2-dependent ubiquitination in vitro and can activate p53 in vivo. Oncogene 19:2312-2323.
42. Momand, J., G. P. Zambetti, D. C. Olson, D. George, and A. J. Levine. 1992. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69:1237-1245.
43. Montes de Oca Luna, R., D. S. Wagner, and G. Lozano. 1995. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 378:203-206.
44. Nacht, M., and T. Jacks. 1996. V(D)J recombination is not required for the development of lymphoma in p53-deficient mice. Cell Growth Differ. 9: 131-138.
45. Oliner, J. D., K. W. Kinzler, P. S. Meltzer, D. L. George, and B. Vogelstein. 1992. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 358:80-83.
46. Oliner, J. D., J. A. Pietenpol, S. Thiagalingam, J. Gyuris, K. W. Kinzler, and B. Vogelstein. 1993. Oncoprotein MDM2 conceals the activation domain of tumor suppressor p53. Nature 362:857-860.
47. Cip1 in muscle and other terminally differentiating cells. Science 267: 1024-1027.
48. MDM2 to destabilize p53. J. Biol. Chem. 275:5733-5738.
49. Prives, C. 1998. Signaling to p53: Breaking the MDM2-p53 circuit. Cell 95:5-8.
50. Roth, J. M., M. Dobbelstein, D. A. Freedman, T. Shenk, and A. J. Levine. 1998. Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein. EMBO J. 17:554-564.
51. Sauer, B., and N. Henderson. 1988. Site-specific DNA recombination in mammalian cells by the Cre recombinase of bacteriophage P1. Proc. Natl. Acad. Sci. USA 85:5166-5170.
52. Schutte, B., M. M. Reynders, C. L. van Assche, P. S. Hupperets, F. T. Bosman, and G. H. Blijham. 1987. An improved method for the immuno-cytochemical detection of bromodeoxyuridine labeled nuclei with flow cytometry. Cytometry 8:372-376.
53. Shinkai, Y., G. Rathbun, K.-P. Lam, E. M. Oltz, V. Stewart, M. Mendelsohn, J. Charron, M. Datta, F. Young, A. M. Stall, and F. W. Alt. 1992. RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement. Cell 68:855-867.
54. Thut, C. J., J. A. Goodrich, and R. Tjian. 1997. Repression of p53-mediated transcription by MDM2: A dual mechanism. Genes Dev. 11:1974-1986.
55. Todaro, G. J., and H. Green. 1963. Qualitative studies of the growth of mouse embryo cells in culture and their development into established cell lines. J. Cell Biol. 17:299-313.
56. Tyner, S. D., S. Venkatachalam, J. Choi, S. Jones, N. Ghebranious, H. Igelmann, X. Lu, G. Soron, B. Cooper, C. Brayton, S. H. Park, T. Thompson, G. Karsenty, A. Bradley, and L. A. Donehower. 2002. p53 mutant mice that display early ageing-associated phenotypes. Nature 415:45-53.
57. Vogelstein, B., D. Lane, and A. J. Levine. 2000. Surfing the p53 network. Nature 408:307-310.
58. Westphal, C. H., K. P. Hoyes, C. E. Canman, X. Huang, M. B. Kastan, J. H. Hendry, and P. Leder. 1998. Loss of atm radiosensitizes multiple p53 null tissues. Cancer Res. 58:5637-5639.
59. Willerford, D. M., W. Swat, and F. W. Alt. 1996. Developmental regulation of V(D)J recombination and lymphocyte differentiation. Curr. Opin. Genet. Dev. 6:603-609.
60. Wu, X., J. H. Bayle, D. Olson, and A. J. Levine. 1993. The p53-mdm-2 autoregulatory feedback loop. Genes Dev. 7:1126-1132.
61. Yonish-Rouach, E., D. Resnitzky, J. Lotem, L. Sachs, A. Kimchi, and M. Oren. 1991. Wild-type p53 induces apoptosis of myeloid leukemic cells that is inhibited by interleukin-6. Nature 352:345-347.